240 results on '"Strnad, Pavel"'
Search Results
2. OS-120 Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
3. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
4. Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework
5. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
6. Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma
7. Alpha-1-Antitrypsin-Mangel – neue therapeutische Optionen bei hepatischer Manifestation
8. Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis
9. The role of desmoglein-2 in kidney disease
10. The keratin-desmosome scaffold of internal epithelia in health and disease – The plot is thickening
11. Alpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ)
12. Th2 Cell Activation in Chronic Liver Disease Is Driven by Local IL33 and Contributes to IL13-Dependent Fibrogenesis
13. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling
14. Contributors
15. Alpha-1 antitrypsin deficiency
16. WED-188 Diagnosis and monitoring pathways using non-invasive tests in patients with alpha-1 antitrypsin deficiency-associated liver disease: results from an expert Delphi panel
17. WED-138 Patients with alpha-1-antitrypsin deficiency and the risk of developing liver events: a longitudinal cohort study
18. FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease
19. TOP-352 Serum proteomics can help identify new prognostic biomarkers in adults with acute liver failure
20. FRI-161 Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease
21. WED-135-YI Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)
22. THU-340-YI Multiomics landscape of alcohol detoxification and the role of PNPLA3 genotype
23. TOP-141 Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management
24. SAT-545 Th2 cell activation in chronic liver disease is driven by local IL-33 and contributes to IL-13 dependent fibrogenesis
25. OS-041-YI A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics
26. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment
27. Phenome of coeliac disease vs. inflammatory bowel disease
28. S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV).
29. Desmoplakin Maintains Transcellular Keratin Scaffolding and Protects From Intestinal Injury
30. Cleaning up alpha-1 antitrypsin deficiency related liver disease
31. A gene silencing-based approach to tackle fatty liver disease
32. Zdravotní tělesná výchova
33. Association of circulating Z‐polymer with adverse clinical outcomes and liver fibrosis in adults with alpha‐1 antitrypsin deficiency
34. Laparoscopic Living donor liver transplantation in irresectable intrahepatic cholangiocarcinoma in primary sclerosing cholangitis associated liver cirrhosis.
35. Serum/Plasma Proteome in Non-Malignant Liver Disease
36. Improved outcomes after hypothermic oxygenated machine perfusion in liver transplantation–Long-term follow-up of a multicenter randomized controlled trial
37. Hepatobiliary phenotype of individuals with chronic intestinal disorders
38. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases
39. Various myosteatosis selection criteria and their value in the assessment of short- and long-term outcomes following liver transplantation
40. Inflammatory activation of surface molecule shedding by upregulation of the pseudoprotease iRhom2 in colon epithelial cells
41. Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease.
42. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
43. Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis
44. Mechanisms and aetiology‐dependent treatment of acute liver failure
45. Generation of two Alpha-I antitrypsin deficiency patient-derived induced pluripotent stem cell lines ISRM-AATD-iPSC-1 (HHUUKDi011-A) and ISRM-AATD-iPSC-2 (HHUUKDi012-A)
46. Alpha-1 antitrypsin (AAT) augmentation and the liver phenotype of adults with AAT deficiency (genotype Pi*ZZ)
47. RNAi Therapeutics for Diseases Involving Protein Aggregation: Fazirsiran for Alpha-1 Antitrypsin Deficiency-associated Liver Disease
48. Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency
49. Association of circulating Z-polymer with adverse clinical outcomes and liver fibrosis in adults with the PiZZ alpha-1 antitrypsin deficiency genotype
50. Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.